Active, not recruitingPhase 2NCT04729322
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
Studying Rare epithelial tumor of small intestine
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Michael J OvermanM.D. Anderson Cancer Center
- Intervention
- Biopsy(procedure)
- Enrollment
- 15 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2027
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04729322 on ClinicalTrials.govOther trials for Rare epithelial tumor of small intestine
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04205968Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersSWOG Cancer Research Network
- ACTIVE NOT RECRUITINGPHASE2NCT02949219Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by SurgeryAcademic and Community Cancer Research United
See all trials for Rare epithelial tumor of small intestine →